These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 22204226)

  • 1. What are the emerging therapeutic alternatives to warfarin in stroke patients? How would the results of RE-LY benefit Pakistanis?
    Khan M; Raza E; Kamal AK
    J Pak Med Assoc; 2011 Jun; 61(6):612-3. PubMed ID: 22204226
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial.
    Wallentin L; Yusuf S; Ezekowitz MD; Alings M; Flather M; Franzosi MG; Pais P; Dans A; Eikelboom J; Oldgren J; Pogue J; Reilly PA; Yang S; Connolly SJ;
    Lancet; 2010 Sep; 376(9745):975-83. PubMed ID: 20801496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Dabigatran versus Warfarin in patients with atrial fibrillation. Results of the RE-LY study].
    Liakishev AA
    Kardiologiia; 2009; 49(10):75-6. PubMed ID: 19845524
    [No Abstract]   [Full Text] [Related]  

  • 4. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial.
    Dans AL; Connolly SJ; Wallentin L; Yang S; Nakamya J; Brueckmann M; Ezekowitz M; Oldgren J; Eikelboom JW; Reilly PA; Yusuf S
    Circulation; 2013 Feb; 127(5):634-40. PubMed ID: 23271794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial.
    Paikin JS; Haroun MJ; Eikelboom JW
    Expert Rev Cardiovasc Ther; 2011 Mar; 9(3):279-86. PubMed ID: 21438804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insights from the dabigatran versus warfarin in patients with atrial fibrillation (RE-LY) trial.
    Khoo CW; Lip GY
    Expert Opin Pharmacother; 2010 Mar; 11(4):685-7. PubMed ID: 20105114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial.
    Diener HC; Connolly SJ; Ezekowitz MD; Wallentin L; Reilly PA; Yang S; Xavier D; Di Pasquale G; Yusuf S;
    Lancet Neurol; 2010 Dec; 9(12):1157-1163. PubMed ID: 21059484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Dabigatran: beyond the RE-LY study].
    García Alegría J
    Rev Clin Esp; 2012 Mar; 212 Suppl 2():1-3. PubMed ID: 23117715
    [No Abstract]   [Full Text] [Related]  

  • 9. Dabigatran etexilate (Pradaxa) for the treatment of atrial fibrillation.
    Belavic JM
    Nurse Pract; 2011 Sep; 36(9):6-7. PubMed ID: 21857210
    [No Abstract]   [Full Text] [Related]  

  • 10. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran.
    Ezekowitz MD; Connolly S; Parekh A; Reilly PA; Varrone J; Wang S; Oldgren J; Themeles E; Wallentin L; Yusuf S
    Am Heart J; 2009 May; 157(5):805-10, 810.e1-2. PubMed ID: 19376304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Warfarin: is the end nigh? Please?
    Neilson RF
    J R Coll Physicians Edinb; 2010 Sep; 40(3):222-3. PubMed ID: 21127766
    [No Abstract]   [Full Text] [Related]  

  • 12. The clinical efficacy of dabigatran etexilate for preventing stroke in atrial fibrillation patients.
    Ellis CR; Kaiser DW
    Vasc Health Risk Manag; 2013; 9():341-52. PubMed ID: 23874100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of dabigatran compared to warfarin in patients with paroxysmal, persistent, and permanent atrial fibrillation: results from the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) study.
    Flaker G; Ezekowitz M; Yusuf S; Wallentin L; Noack H; Brueckmann M; Reilly P; Hohnloser SH; Connolly S
    J Am Coll Cardiol; 2012 Feb; 59(9):854-5. PubMed ID: 22361407
    [No Abstract]   [Full Text] [Related]  

  • 14. Should dabigatran replace warfarin for stroke prevention in AF?
    Drug Ther Bull; 2011 Oct; 49(10):114-7. PubMed ID: 21994438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dabigatran v warfarin. Compare with higher standard.
    Edwards D
    BMJ; 2010 Oct; 341():c5984. PubMed ID: 20978048
    [No Abstract]   [Full Text] [Related]  

  • 16. Dabigatran etexilate: a pharmacoeconomic review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.
    McKeage K
    Pharmacoeconomics; 2012 Sep; 30(9):841-55. PubMed ID: 22734683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do ingredients make the difference?: finding the best cocktail of an anticoagulant with antiplatelets.
    Sinnaeve PR; Van de Werf F
    Circulation; 2013 Feb; 127(5):566-8. PubMed ID: 23271795
    [No Abstract]   [Full Text] [Related]  

  • 18. Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation.
    Ezekowitz MD; Wallentin L; Connolly SJ; Parekh A; Chernick MR; Pogue J; Aikens TH; Yang S; Reilly PA; Lip GY; Yusuf S;
    Circulation; 2010 Nov; 122(22):2246-53. PubMed ID: 21147728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atrial fibrillation: A promising new anticoagulant for stroke prevention.
    Spinler SA
    Nat Rev Cardiol; 2010 Jan; 7(1):10-1. PubMed ID: 20019756
    [No Abstract]   [Full Text] [Related]  

  • 20. [Improvements in oral anticoagulant therapy for atrial fibrillation].
    Briongos Figuero S; García Santos-Gallego C; Badimón JJ
    Med Clin (Barc); 2013 Dec; 141(11):487-93. PubMed ID: 23597953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.